Factory Mutual Insurance Co. Has $10.07 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Factory Mutual Insurance Co. decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 36.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,500 shares of the medical equipment provider’s stock after selling 11,800 shares during the quarter. Factory Mutual Insurance Co.’s holdings in Intuitive Surgical were worth $10,071,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares during the last quarter. Capital World Investors grew its holdings in shares of Intuitive Surgical by 1.0% during the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Jennison Associates LLC lifted its stake in Intuitive Surgical by 4.6% in the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after purchasing an additional 198,483 shares during the last quarter. Fisher Asset Management LLC boosted its position in Intuitive Surgical by 1.9% in the fourth quarter. Fisher Asset Management LLC now owns 4,488,048 shares of the medical equipment provider’s stock valued at $1,514,088,000 after buying an additional 82,652 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Intuitive Surgical by 3.0% during the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after buying an additional 70,556 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $0.94 during trading on Friday, reaching $484.78. 1,170,154 shares of the stock were exchanged, compared to its average volume of 1,469,034. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.48. The stock has a fifty day moving average of $480.34 and a two-hundred day moving average of $434.94. The firm has a market cap of $172.27 billion, a price-to-earnings ratio of 83.30, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,120 shares of company stock worth $25,528,753. Corporate insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the topic of several recent research reports. Robert W. Baird raised their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Evercore ISI upped their price target on shares of Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Morgan Stanley raised their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Citigroup boosted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Truist Financial raised their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $458.35.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.